# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while ut...
Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, Cle...
All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before...
B of A Securities analyst Geoff Meacham maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target fr...
Needham analyst Joseph Stringer maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target from $35 t...